These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Contextual role of E2F1 in suppression of melanoma cell motility and invasiveness. Meng P; Bedolla RG; Yun H; Fitzpatrick JE; Kumar AP; Ghosh R Mol Carcinog; 2019 Sep; 58(9):1701-1710. PubMed ID: 31124185 [TBL] [Abstract][Full Text] [Related]
8. Gene expression analyses of primary melanomas reveal CTHRC1 as an important player in melanoma progression. Eriksson J; Le Joncour V; Nummela P; Jahkola T; Virolainen S; Laakkonen P; Saksela O; Hölttä E Oncotarget; 2016 Mar; 7(12):15065-92. PubMed ID: 26918341 [TBL] [Abstract][Full Text] [Related]
9. Targeting BRAF for patients with melanoma. Arkenau HT; Kefford R; Long GV Br J Cancer; 2011 Feb; 104(3):392-8. PubMed ID: 21139585 [TBL] [Abstract][Full Text] [Related]
11. [Future targeting of the RAS/RAF/MEK/ERK signaling pathway in oncology: the example of melanoma]. Favre G Bull Acad Natl Med; 2014 Feb; 198(2):321-36; discussion 337-8. PubMed ID: 26263707 [TBL] [Abstract][Full Text] [Related]
12. Podoplanin drives dedifferentiation and amoeboid invasion of melanoma. de Winde CM; George SL; Crosas-Molist E; Hari-Gupta Y; Arp AB; Benjamin AC; Millward LJ; Makris S; Carver A; Imperatore V; Martínez VG; Sanz-Moreno V; Acton SE iScience; 2021 Sep; 24(9):102976. PubMed ID: 34485858 [TBL] [Abstract][Full Text] [Related]
13. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells. Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506 [TBL] [Abstract][Full Text] [Related]
14. BET inhibitor suppresses melanoma progression Deng G; Zeng F; Su J; Zhao S; Hu R; Zhu W; Hu S; Chen X; Yin M Theranostics; 2020; 10(25):11428-11443. PubMed ID: 33052224 [No Abstract] [Full Text] [Related]
15. Surgical treatment options for stage IV melanoma. Wei IH; Healy MA; Wong SL Surg Clin North Am; 2014 Oct; 94(5):1075-89, ix. PubMed ID: 25245969 [TBL] [Abstract][Full Text] [Related]
16. The Emerging Therapeutic Landscape of Advanced Melanoma. Henriques V; Martins T; Link W; Ferreira BI Curr Pharm Des; 2018; 24(5):549-558. PubMed ID: 29366407 [TBL] [Abstract][Full Text] [Related]
17. Melanoma: molecular pathogenesis and emerging target therapies (Review). Russo AE; Torrisi E; Bevelacqua Y; Perrotta R; Libra M; McCubrey JA; Spandidos DA; Stivala F; Malaponte G Int J Oncol; 2009 Jun; 34(6):1481-9. PubMed ID: 19424565 [TBL] [Abstract][Full Text] [Related]
18. Podoplanin Drives Amoeboid Invasion in Canine and Human Mucosal Melanoma. Shinada M; Kato D; Motegi T; Tsuboi M; Ikeda N; Aoki S; Iguchi T; Li T; Kodera Y; Ota R; Hashimoto Y; Takahashi Y; Chambers J; Uchida K; Kato Y; Nishimura R; Nakagawa T Mol Cancer Res; 2023 Nov; 21(11):1205-1219. PubMed ID: 37493578 [TBL] [Abstract][Full Text] [Related]
19. Cancer cell-derived long pentraxin 3 (PTX3) promotes melanoma migration through a toll-like receptor 4 (TLR4)/NF-κB signaling pathway. Rathore M; Girard C; Ohanna M; Tichet M; Ben Jouira R; Garcia E; Larbret F; Gesson M; Audebert S; Lacour JP; Montaudié H; Prod'Homme V; Tartare-Deckert S; Deckert M Oncogene; 2019 Jul; 38(30):5873-5889. PubMed ID: 31253871 [TBL] [Abstract][Full Text] [Related]
20. Preliminary results from a prospective trial of preoperative combined BRAF and MEK-targeted therapy in advanced BRAF mutation-positive melanoma. Johnson AS; Crandall H; Dahlman K; Kelley MC J Am Coll Surg; 2015 Apr; 220(4):581-93.e1. PubMed ID: 25797743 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]